Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

about

Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells.Profiling the miRNA-mRNA-lncRNA interaction network in MSC osteoblast differentiation induced by (+)-cholesten-3-one

P2860

Q54982598-D2A2C68B-F782-4509-898F-52BAB1A312E0 Q58101194-225BA15C-DBE6-47EA-BDFC-BF87CE005A85

P2860

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

Item

http://www.wikidata.org/entity/Q41548439

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Lenalidomide restores the oste ...... ating Notch signaling pathway.

@en

type

Item

label

Lenalidomide restores the oste ...... ating Notch signaling pathway.

@en

prefLabel

Lenalidomide restores the oste ...... ating Notch signaling pathway.

@en

P1476

Lenalidomide restores the oste ...... vating Notch signaling pathway

@en

P2093

Chengming Fei

http://www.w3.org/2001/XMLSchema#string

Dong Wu

http://www.w3.org/2001/XMLSchema#string

Jiying Su

http://www.w3.org/2001/XMLSchema#string

Juan Guo

http://www.w3.org/2001/XMLSchema#string

Qingqing Zheng

http://www.w3.org/2001/XMLSchema#string

Sida Zhao

http://www.w3.org/2001/XMLSchema#string

Xiao Li

http://www.w3.org/2001/XMLSchema#string

Youshan Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Notch signaling: cell fate control and signal integration in development

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling

Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.

Advances in the understanding of myeloma bone disease and tumour growth.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

HES1 (hairy and enhancer of split 1) is a determinant of bone mass

Notch signaling and the bone marrow hematopoietic stem cell niche.

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Notch-Hes pathway mediates the impaired osteogenic differentiation of bone marrow mesenchymal stromal cells from myelodysplastic syndromes patients through the down-regulation of Runx2.

P304

55405-55421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.19265

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Chunkang Chang

P577

2017-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903429

http://www.w3.org/2001/XMLSchema#string

P932

5589668

http://www.w3.org/2001/XMLSchema#string

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

about

P2860

P2860

Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932